1217862-29-7Relevant articles and documents
Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as huntington's disease
Ernst, Justin T.,Neubert, Timothy,Liu, Michael,Sperry, Samuel,Zuccola, Harmon,Turnbull, Amy,Fleck, Beth,Kargo, William,Woody, Lisa,Chiang, Peggy,Tran, Dao,Chen, Weichao,Snyder, Phillip,Alcacio, Timothy,Nezami, Azin,Reynolds, James,Alvi, Khisal,Goulet, Lance,Stamos, Dean
, p. 3382 - 3400 (2014/05/20)
A structure-based drug design strategy was used to optimize a novel benzolactam series of HSP90α/β inhibitors to achieve >1000-fold selectivity versus the HSP90 endoplasmic reticulum and mitochondrial isoforms (GRP94 and TRAP1, respectively). Selective HS